Oromucosol Phytocannabinoid Spray

Ever since our first Clinical Conference on Cannabis Therapeutics in 2000, Patients Out of Time has followed the progress of GW Pharmaceuticals (UK) and it's development of a oromucosol spray consisting of phytocannabinoids (extracted from the natural plant), marketed as Sativex_TM.

Video - Medical Cannabis Strains - Geoffrey Guy, MD (GW Pharmaceuticals, U.K) -

The founder of GW Pharmaceuticals, Geoffrey Guy , MD attended our Second conference in Portland, Oregon in May 0f 2002. First discussing CB1 and CB2 receptors; the modulatory effect on dopamine, GABA and glutamate; and cross-talk with other receptors, Dr. Guy then examines Phyto-Cannabinoids (plant based) THC, CBD and others, with GW's success in producing whole extracts from 3 tons/ year of dried marijuana and years of genetic breeding to feature both high THC and high CBD strains. Extracts from these strains are then blended for efficacy and synergistic moderation of side-effects. Dr. Guy then reports on Phase 2 trials, with good results including an "excellent safety profile" and emerging Cannabinoid-Ratio-Specific therapeutic themes.

Dr. Geoffrey Guy returns to our Third Clinical Conference on Cannabis Therapeutics, in Charlottesville VA, May of 2004, relating progress in their product development and clinical trials.

Video - Oromuscosal Cannabis-based Medicine, Geoffrey Guy, MD -

"From Plant to Prescription Medicine" - Introduced by Don Wirtshafter, Geoffrey Guy, MD, Founder and Executive Chairman of GW Pharmaceuticals, UK, explains why extracts of Phyto-Cannabinoids THC & CBD need to represent the natural balance of the Cannabis plant. Describing Cannabinoid action as a "Super-Modulator", Dr. Guy discusses clinical trials involving Multiple Sclerosis (MS), spinal cord injury and neuropathic pain.

Research Articles on Cannabis-Based Oromucosol Spray

Notcutt, W., Price, M., Miller, R., Newport, S., Phillips, C., Simmonds, S., et al. (2004). Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 "N of 1" studies. Anaesthesia, 59, 440-452.

Notcutt, W. G., Sharief, M., Mutiboko, I., Hawkes, C., Bolt, J., & Sarantis, N. (2006). Cannabis based medicine (Sativex) for chronic pain due to multiple sclerosis or other neurological dysfunction: a randomised controlled trial. European Journal of Pain, (in press).

Nurmikko, T. J., Serpell, M. G., Hoggart, B., Toomey, P. J., & Morlion, B. J. (2005). A multi-center, double-blind, randomized, placebo-controlled trial of oro-mucosal cannabis-based medicine in the treatment of neuropathic pain characterized by allodynia. Neurology, 64(6, Suppl. 1), A374.

Rog, D. J., Nurmiko, T., Friede, T., & Young, C. (2005). Randomized controlled trial of cannabis based medicine in central neuropathic pain due to multiple sclerosis. Neurology, 65(6), 812-819.

Russo, E. B., Guy, G. W., & Robson, P. J. (2007). Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex((R)), a Cannabis-Based Medicine. Chem Biodivers, 4(8), 1729-1743.